Both forms are aggressive, with ALK+ ALCL in young people being responsive to chemotherapy and showing an approximate 70% long-term survival, while ALK- ALCL, usually seen in older adults, has a less favorable prognosis. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.